The purpose of this article is to describe the effects of the pediatric antidepressant controversy on the Treatment of Serotonin-Selective Reuptake Inhibitor (SSRI) Resistant Depression in Adolescents (TORDIA) trial.
Method:
Adolescents, ages 12–18 years, with SSRI resistant depression were randomized to one of four treatments for a 12 week trial: Switch to different SSRI, switch to an alternate antidepressant (venlafaxine), switch to an alternate SSRI plus cognitive behavior therapy (CBT), or switch to venlafaxine plus CBT.
Results:
The health advisories and “black box” warnings regarding suicidality and antidepressants in adolescents occurred during the course of the TORDIA trial. Revisions to the protocol, multiple-consent form changes, and re-consenting of patients were necessary. Recruitment of participants was adversely affected.
Conclusion:
Despite a cascade of unforeseen events that delayed the completion of the study, the TORDIA trial resulted in clinically important information about treatment-resistant depression in adolescents.
Get full access to this article
View all access options for this article.
References
1.
AsarnowJR, EmslieG, ClarkeG, WagnerKD, SpiritoA, VitielloB, IyengarS, ShamseddeenW, RitzL, MccrackenJ, StroberM, SuddathR, LeonardH, PortaG, KellerM, BrentD: Treatment of selective serotonin reuptake inhibitor-resistant depression in adolescents: Predictors and moderators of treatment response. J Am Acad Child Adolesc Psychiatry, 48:330–339, 2009.
2.
BrentD, EmslieG, ClarkeG, WagnerKD, AsarnowJR, KellerM, VitielloB, RitzL, IyengarS, AbebeK, BirmaherB, RyanN, KennardB, HughesC, DeBarL, McCrackenJ, StroberM, SuddathR, SpiritoA, LeonardH, MelhemN, PortaG, OnoratoM, ZelaznyJ: Switching to another SSRI or to venlafaxine with or without cognitive behavioral therapy for adolescents with SSRI-resistant depression: The TORDIA randomized controlled trial. JAMA, 299:901–913, 2008.
3.
BrentD, MelhemN, FerrellR, EmslieG, WagnerKD, RyanN, VitielloB, BirmaherB, MayesT, ZelaznyJ, OnoratoM, DevlinB, ClarkeG, DeBarL, KellerM: Association of FKBP5 polymorphisms with suicidal events in the Treatment of Resistant Depression in Adolescents (TORDIA) study. Am J Psychiatry, 167:190–197, 2010.
4.
BrentDA, EmslieGJ, ClarkeGN, AsarnowJ, SpiritoA, RitzL, VitielloB, IyengarS, BirmaherB, RyanND, ZelaznyJ, OnoratoM, KennardB, MayesTL, DebarLL, McCrackenJT, StroberM, SuddathR, LeonardH, PortaG, KellerMB: Predictors of spontaneous and systematically assessed suicidal adverse events in the treatment of SSRI-resistant depression in adolescents (TORDIA) study. Am J Psychiatry, 166:418–426, 2009.
5.
CurtisBM, BarrettBJ, ParfreyPS: The design of randomized controlled trials. Methods Mol Biol, 473:95–111, 2009.
FieldMJ, BehrmanRE: Ethical Conduct of Clinical Research Involving Children. Washington, DC: The National Academies Press; 2004.
8.
FuhrerMJ: Conducting multiple-site clinical trials in medical rehabilitation research. Am J Phys Med Rehabil, 84:823–831, 2005.
9.
FurimskyI, CheungAH, DewaCS, ZipurskyRB: Strategies to enhance patient recruitment and retention in research involving patients with a first episode of mental illness. Contemp Clin Trials, 29:862–866, 2008.
10.
GoldJL, DewaCS: Institutional review boards and multisite studies in health services research: Is there a better way?. Health Serv Res, 40:291–307, 2005.
11.
GoldsteinBI, ShamseddeenW, SpiritoA, EmslieG, ClarkeG, WagnerKD, AsarnowJR, VitielloB, RyanN, BirmaherB, MayesT, OnoratoM, ZelaznyJ, BrentDA: Substance use and the treatment of resistant depression in adolescents. J Am Acad Child Adolesc Psychiatry, 48:1182–1192, 2009.
KoelchM, SingerH, PrestelA, BurkertJ, SchulzeU, FegertJM: “… because I am something special” or “I think I will be something like a guinea pig”: Information and assent of legal minors in clinical trials—assessment of understanding, appreciation and reasoning. Child Adolesc Psychiatry Ment Health, 3:2, 2009.
14.
LynchFL, DickersonJF, ClarkeG, VitielloB, PortaG, WagnerKD, EmslieG, AsarnowJRJr., KellerMB, BirmaherB, RyanND, KennardB, MayesT, DebarL, McCrackenJT, StroberM, SuddathRL, SpiritoA, OnoratoM, ZelaznyJ, IyengarS, BrentD: Incremental cost-effectiveness of combined therapy vs medication only for youth with selective serotonin reuptake inhibitor-resistant depression: Treatment of SSRI-resistant depression in adolescents trial findings. Arch Gen Psychiatry, 68:253–262, 2011.
15.
McClureCA, GrayG, RybczykGK, WrightPF: Challenges to conducting HIV preventative vaccine trials with adolescents. J Acquir Immune Defic Syndr, 36:726–733, 2004.
16.
McIntoshN, BatesP, BrykczynskaG, DunstanG, GoldmanA, HarveyD, LarcherV, McCraeD, McKinnonA, PattonM, SaundersJ, ShelleyP: Guidelines for the ethical conduct of medical research involving children. Royal College of Paediatrics, Child Health: Ethics Advisory Committee. Arch Dis Child, 82:177–182, 2000.
17.
Medicines and Health Care Products Regulatory Agency: Safety of seroxat (paroxetine) in children and adolescents under 18 years-contraindication in the treatment of depressive illness. Message from Professor G Duff, Chairman of the committee on safety of medicines. June 10, 2003a. www.mhra.gov.uk/home/groups/pl-p/documents/websiteresources/con019507.pdf. Accessed March17, 2011.
18.
Medicines and Health Care Products Regulatory Agency: Safety of velafaxine in children and adolescents under 18 years in the treatment of depressive illness. Message from Professor G Duff, Chairman of the committee on safety of medicines. September 19, 2003b. www.mhra.gov.uk/home/groups/pl-p/documents/websiteresources/con019501.pdf. Accessed March17, 2011.
19.
PosnerK, OquendoMA, StanleyB, DaviesM, GouldM: Columbia Classification Algorithm of Suicide Assessment (C-CACA): Classification of suicidal events in the FDA's pediatric suicidal risk analysis of antidepressants. Am J Psychiatry, 164:1035–1043, 2007.
20.
SakolskyDJ, PerelJM, EmslieGJ, ClarkeGN, WagnerKD, VitielloB, KellerMB, BirmaherB, AsarnowJR, RyanND, McCrackenJT, StroberMJ, IyengarS, PortaG, BrentDA: Antidepressant exposure as a predictor of clinical outcomes in the Treatment of Resistant Depression in Adolescents (TORDIA) study. J Clin Psychopharmacol, 31:92–97, 2011.
21.
ShamseddeenW, AsarnowJR, ClarkeG, VitielloB, WagnerKD, BirmaherB, KellerMB, EmslieG, IyengarS, RyanND, McCrackenJT, PortaG, MayesT, BrentDA: Impact of physical and sexual abuse on treatment response in the treatment of resistant depression in adolescent study (TORDIA). J Am Acad Child Adolesc Psychiatry, 50:293–301, 2011.
22.
TanJO, KoelchM: The ethics of psychopharmacological research in legal minors. Child Adolesc Psychiatry Ment Health, 2:39, 2008.
23.
U.S. Food and Drug Administration. FDA Public Health Advisory, reports of suicidality in pediatric patients being treated with antidepressant medications for major depressive disorder (MDD). October 27, 2003a. www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/PublicHealthAdvisories/ucm168828.htm. Accessed March17, 2011.
24.
U.S. Food and Drug Administration. FDA Statement regarding the anti-depressant paxil for pediatric population. FDA Talk Paper. June 19, 2003b. www.ahrp.org/infomail/0603/19a.php. Accessed March17, 2011.
25.
U.S. Food and Drug Administration: FDA Public Health Advisory: FDA launches a multi-pronged strategy to strengthen safeguards for children treated with antidepressant medications. October 15, 2004a. www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2004/ucm108363.htm. Accessed March17, 2011.
26.
U.S. Food and Drug Administration. FDA Public Health Advisory, worsening depression and suicidality in patients being treated with antidepressant medications. March 22, 2004b. www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/PublicHealthAdvisories/ucm161696.htm. Accessed March17, 2011.
27.
U.S. Food and Drug Administration: Public Health Advisory—Combined use of 5-hydroxytryptamine receptor agonists (triptans), selective serotonin reuptake inhibitors (SSRIs) or selective serotonin/norepinephrine reuptake inhibitors (SNRIs) may result in life-threatening serotonin syndrome. July 19, 2006a. www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/PublicHealthAdvisories/ucm124349.htm. Accessed March17, 2011.
28.
U.S. Food and Drug Administration: Public Health Advisory: Treatment challenges of depression in pregnancy and the possibility of persistent pulmonary hypertension in newborns. July 19, 2006b. www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/PublicHealthAdvisories/ucm124348.htm. Accessed March17, 2011.
29.
VitielloB, EmslieG, ClarkeG, WagnerKD, AsarnowJR, KellerMB, BirmaherB, RyanND, KennardB, MayesTL, DebarL, LynchF, DickersonJ, StroberM, SuddathR, McCrackenJT, SpiritoA, OnoratoM, ZelaznyJ, PortaG, IyengarS, BrentDA: Long-term outcome of adolescent depression initially resistant to selective serotonin reuptake inhibitor treatment: A follow-up study of the TORDIA sample. J Clin Psychiatry, 72:388–396, 2011.
30.
WagnerKD, MartinezM, JoinerT: Youths' and their parents' attitudes and experiences about participation in psychopharmacology treatment research. J Child Adolesc Psychopharmacol, 16:298–307, 2006.
31.
WolduH, PortaG, GoldsteinT, SakolskyD, PerelJ, EmslieG, MayesT, ClarkeG, RyanND, BirmaherB, WagnerKD, AsarnowJR, KellerMB, BrentD: Pharmacokinetically and clinician-determined adherence to an antidepressant regimen and clinical outcome in the TORDIA trial. J Am Acad Child Adolesc Psychiatry, 50:490–498, 2011.
32.
Wyeth Pharmaceuticals: Letter to health professionals. August 22, 2003. www.antidepressantsfacts.com/2003-08-22-Wyeth-Effexor-kids.pdf. Accessed March17, 2011.
33.
Wyeth Pharmaceuticals: Letter to health professionals. June 3, 2004. www.fda.gov/downloads/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/UCM166425.pdf. Accessed March17, 2011.
34.
Wyeth Pharmaceuticals: Letter to health professionals. October 17, 2006. www.fda.gov/downloads/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/UCM153177.pdf. Accessed March17, 2011.
